As of 2025-11-20, the Relative Valuation of 10X Genomics Inc (TXG) is (17.53) USD. This relative valuation is based on P/E multiples. With the latest stock price at 15.65 USD, the upside of 10X Genomics Inc based on Relative Valuation is -212.0%.
The range of the Relative Valuation is (16.52) - (17.41) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 25.8x - 33.1x | 29.6x |
| Forward P/E multiples | 26.9x - 28.4x | 27.6x |
| Fair Price | (16.52) - (17.41) | (17.53) |
| Upside | -205.5% - -211.3% | -212.0% |
| Date | P/E |
| 2025-11-19 | -25.33 |
| 2025-11-18 | -25.38 |
| 2025-11-17 | -25.61 |
| 2025-11-14 | -25.92 |
| 2025-11-13 | -26.67 |
| 2025-11-12 | -27.22 |
| 2025-11-11 | -27.06 |
| 2025-11-10 | -27.86 |
| 2025-11-07 | -24.88 |
| 2025-11-06 | -21.21 |
| 2025-11-05 | -22.00 |
| 2025-11-04 | -21.79 |
| 2025-11-03 | -22.35 |
| 2025-10-31 | -22.25 |
| 2025-10-30 | -20.29 |
| 2025-10-29 | -21.04 |
| 2025-10-28 | -21.76 |
| 2025-10-27 | -22.17 |
| 2025-10-24 | -22.46 |
| 2025-10-23 | -21.79 |
| 2025-10-22 | -20.00 |
| 2025-10-21 | -21.25 |
| 2025-10-20 | -21.43 |
| 2025-10-17 | -19.30 |
| 2025-10-16 | -20.19 |
| 2025-10-15 | -19.39 |
| 2025-10-14 | -18.82 |
| 2025-10-13 | -18.92 |
| 2025-10-10 | -18.71 |
| 2025-10-09 | -19.10 |
| 2025-10-08 | -19.69 |
| 2025-10-07 | -18.92 |
| 2025-10-06 | -20.62 |
| 2025-10-03 | -20.80 |
| 2025-10-02 | -20.08 |
| 2025-10-01 | -20.21 |
| 2025-09-30 | -19.07 |
| 2025-09-29 | -18.50 |
| 2025-09-26 | -19.12 |
| 2025-09-25 | -19.49 |
| 2025-09-24 | -19.67 |
| 2025-09-23 | -20.37 |
| 2025-09-22 | -21.27 |
| 2025-09-19 | -21.27 |
| 2025-09-18 | -21.65 |
| 2025-09-17 | -20.98 |
| 2025-09-16 | -21.42 |
| 2025-09-15 | -21.78 |
| 2025-09-12 | -20.62 |
| 2025-09-11 | -21.30 |